Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Astellas, J&J Link For Arthritis Drug
by Lisa M. Jarvis
October 8, 2012
| A version of this story appeared in
Volume 90, Issue 41
Janssen Biotech, the R&D arm of Johnson & Johnson, will pay Japan’s Astellas Pharma $65 million for access to ASP015K, a JAK inhibitor in Phase II trials as a rheumatoid arthritis treatment. Janssen, which gains rights to develop the small-molecule compound everywhere but Japan, will pay for future clinical studies. Astellas could reap another $880 million in milestone and royalty payments if ASP015K reaches the market. Pfizer is awaiting FDA approval for tofacitinib, its own JAK inhibitor for arthritis.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X